Annovis Bio, Inc. (NYSE: ANVS) – Form 8-K Filing Analysis

Key Highlights from the SEC Filing

• Filing Type: Current Report (Form 8-K)
• Date of Report: March 23, 2026
• Company Name: Annovis Bio, Inc.
• Trading Symbol: ANVS
• Exchange: New York Stock Exchange
• CIK: 0001477845
• File Number: 001-39202
• Tax Identification Number: 26-2540421
• Business Address: 101 Lindenwood Drive, Suite 225, Malvern, PA 19355
• Former Name: QR Pharma, Inc. (name changed on December 2, 2009)

Potentially Price-Sensitive Information

• Item 5.02 – Departure or Appointment of Directors/Officers:
  • The filing indicates a disclosure under Item 5.02, which covers the departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements. However, the detailed description of the event (such as the name of the officer/director involved, the nature of departure/appointment, or compensation arrangements) is missing from the provided excerpt.
  • Shareholders should note that changes in executive leadership, board composition, or compensation arrangements can sometimes be price-sensitive, especially if they signal strategic shifts or impact investor confidence.
• No Amendment Flag: The report is not an amendment; it is an original filing.
• Emerging Growth Company Status: Annovis Bio, Inc. is not classified as an emerging growth company, which means it is subject to full reporting requirements and has not elected to use the extended transition period for complying with new or revised financial accounting standards.

Other Regulatory Disclosures

• Written Communications: The filing does not contain written communications pursuant to Rule 425 under the Securities Act.
• Soliciting Material: The filing does not contain soliciting material pursuant to Rule 14a-12 under the Exchange Act.
• Pre-commencement Tender Offer: The filing does not contain pre-commencement communication pursuant to Rule 14d-2(b) or Rule 13e-4(c) under the Exchange Act.
• Security Details: Annovis Bio’s common stock, par value \$0.0001 per share, is registered on the NYSE under the symbol ANVS.

Shareholder Takeaways

• The Form 8-K filing is a routine regulatory disclosure.
• The only potentially price-sensitive item is the reference to Item 5.02 concerning directors or officers. However, as the document does not provide specific details about the event, investors should monitor for further disclosures or press releases from the company.
• There is no evidence of material events such as mergers, acquisitions, bankruptcy, or other significant corporate actions in this report.
• The company’s compliance status and absence of emerging growth company privileges may affect future reporting and accounting practices, but this is standard for many public companies.

Conclusion

Based on the information available from the Form 8-K filing, there is no significant or actionable news that would be expected to materially move Annovis Bio, Inc.’s share price at this time. Investors are advised to await further details, particularly regarding Item 5.02 events, which could become price-sensitive if and when more information is released.

Disclaimer

The above article is based solely on information contained in the SEC Form 8-K filing as of March 23, 2026. It does not constitute investment advice and should not be relied upon as such. Investors should consult official company releases and their financial advisors before making any investment decisions. The author has made reasonable efforts to interpret the available data but cannot guarantee completeness or accuracy.

View Annovis Bio, Inc. Historical chart here